Investors & Media

Transformative science, targeted medicines

We are working to advance a deep pipeline of precision therapies, designed to allow patients to live longer, better lives. Our approach combines world-leading expertise in protein kinases with sound execution and an intense focus on discovery.

SEC filing details

Document Details

Form
SC 13G
Filing Date
May 8, 2015
Document Date
May 8, 2015
Form Description
A statement of beneficial ownership of common stock by certain persons
Filing Group
Other
Company
Blueprint Medicines Corp.
Issuer
Blueprint Medicines Corp